On August 20, 2020 Junshi Biosciences, a Shanghai biopharma, reported a JV with Nanjing’s Impact Therapeutics to develop Impact’s PARP inhibitor (Press release, ChinaBio, AUG 20, 2020, View Source [SID1234563932]). Junshi will contribute $43 million for 50% of the JV while Impact will add Greater China rights to IMP4297, the company’s clinical-stage PARP inhibitor. The two companies will collaborate on conducting clinical trials of the candidate in multiple indications, starting with ovarian cancer, plus preparing for manufacturing and commercialization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!